Clinical Trials on Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

Total 1182 results

National Cancer Institute (NCI)

Recruiting

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Neuroblastoma | Ganglioneuroblastoma, Nodular

United States
Brigham and Women's Hospital
National Cancer Institute (NCI); Dana-Farber Cancer Institute; University of...

Recruiting

MCT for the Harvard/UCSF ROBIN Center

Neuroblastoma | Glioma, Childhood Brainstem

United States
Giselle Sholler
Y-mAbs

Recruiting

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

High-risk Neuroblastoma

United States, Canada
EusaPharma (UK) Limited
United BioSource, LLC

Recruiting

A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta

Neuroblastoma

France, Germany, United Kingdom, Italy, Austria, Poland, Spain
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Neuroblastoma | Ganglioneuroblastoma, Nodular

United States, Australia, Canada, New Zealand
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor

Ewing Sarcoma | Ewing-Like Sarcoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Recruiting

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Neuroblastoma | Pheochromocytoma

United States
University of Texas Southwestern Medical Center

No longer available

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

Relapsed Neuroblastoma | Metastatic Pheochromocytoma

United States
Samsung Medical Center

Recruiting

Response-based Treatment of High-risk Neuroblastoma

Newly Diagnosed High Risk Neuroblastoma

Korea, Republic of
Gustave Roussy, Cancer Campus, Grand Paris
Erasmus Medical Center; Catholic University of the Sacred Heart; St. Anna Kinderkrebsforschung

Completed

Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours (TOTEM2)

Neuroblastoma | Solid Tumors | Brain Tumors

France
Yizhuo Zhang

Recruiting

Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood. (CSIIT-Q36)

Neuroblastoma in Children

China
Samsung Medical Center
Ministry of Health, Republic of Korea

Unknown

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

High Risk Neuroblastoma
University Hospital, Strasbourg, France

Recruiting

Dinutuximab Beta at the HUS and the Toulouse Oncopole (DNB)

Neuroblastoma

France
Emory University

Recruiting

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma (Aflac-NBL-2002)

Neuroblastoma | Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Clarity Pharmaceuticals Ltd

Recruiting

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Neuroblastoma | Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Columbia University
Instituto de Tratamento do Câncer Infantil

Completed

Nutritional Status in Neuroblastoma in Sao Paolo, Brazil

Neuroblastoma

Brazil
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Terminated

Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction (VERITAS)

Very High Risk Neuroblastoma

Italy, Austria, France, Netherlands, Spain
Children's Hospital Los Angeles
National Cancer Institute (NCI)

Completed

N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma

Neuroblastoma

United States
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI)

Completed

N99-02: Melphalan and Buthionine Sulfoximine (BSO)

Neuroblastoma

Canada, United States
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI)

Completed

N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

Neuroblastoma

United States
Nant Operations Center
National Cancer Institute (NCI)

Completed

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma (IV Fenretinide)

Neuroblastoma

United States, Canada
University of Michigan Rogel Cancer Center
Millennium Pharmaceuticals, Inc.

Completed

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

Neuroblastoma

United States
Sinobioway Cell Therapy Co., Ltd.
Children's Hospital of Fudan University; Nanjing Children's Hospital

Unknown

Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children

Relapsed or Refractory Neuroblastoma

China
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Samples From Young Patients With Neuroblastoma

Neuroblastoma
Children's Oncology Group
National Cancer Institute (NCI)

Completed

hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Neuroblastoma

United States, Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy Plus Etoposide in Treating Patients With Neuroblastoma

Neuroblastoma

United States
Children's Cancer and Leukaemia Group

Unknown

Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 Neuroblastoma

Neuroblastoma

United Kingdom
Gesellschaft fur Padiatrische Onkologie und Hamatologie...

Unknown

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Neuroblastoma

Germany, Switzerland
Memorial Sloan Kettering Cancer Center

Completed

Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Multiple Therapies in Treating Patients With Advanced Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment

Neuroblastoma

United States
Children's Hospital Los Angeles
National Cancer Institute (NCI)

Completed

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

Neuroblastoma

United States
Nationwide Children's Hospital
Exelixis

Recruiting

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Sarcoma | Neuroblastoma

United States
Hong Kong Children's Hospital
The University of Hong Kong

Recruiting

Quadruple Immunotherapy for Neuroblastoma

Neuroblastoma Recurrent

Hong Kong
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital; Shandong Cancer Hospital...

Recruiting

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

B7-H3-positive Relapsed/ Refractory Neuroblastoma

China
University Children's Hospital Tuebingen

Completed

CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma

Neuroblastoma Recurrent

Germany, Austria
University of Regensburg

Completed

Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma (RIST-rNB-2011)

Neuroblastoma Recurrent

Germany
Shenzhen Geno-Immune Medical Institute
Shenzhen Children's Hospital

Recruiting

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Neuroblastoma

China
Institut Claudius Regaud
Advanced Accelerator Applications

Recruiting

A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. (NEUROBLU 02)

Neuroblastoma

France
Children's Hospital Los Angeles
National Cancer Institute (NCI)

Completed

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Neuroblastoma

Canada, United States
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI)

Completed

N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

Neuroblastoma

United States, Canada
Molecular Insight Pharmaceuticals, Inc.

Completed

N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Neuroblastoma

United States
Burzynski Research Institute

Terminated

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma

Neuroblastoma

United States
Children's Hospital Los Angeles
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Children With Neuroblastoma

Neuroblastoma

United States
Centre Oscar Lambret
Novartis Pharmaceuticals; National Cancer Institute, France

Completed

Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma (MIITOP)

Neuroblastoma

France
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying Biomarkers in Samples From Patients With High-Risk Neuroblastoma

Neuroblastoma
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Gene Expression in Predicting Outcome in Samples From Patients With High-Risk Neuroblastoma

Neuroblastoma
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma

Neuroblastoma

United States

Clinical Trials on Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations